XBP1 and diffuse large B-cell lymphoma: In resistant phenotypes of DLBCL or MM, decreased levels of XBP1 can be observed, but it has not yet been established whether this is only the effect of exposure to the drug or a compensatory mechanism that induces resistance in treated cells.